Literature DB >> 7995331

Changes in clearance create pharmacokinetic pitfalls as illustrated by studies on tiopronin.

P A Sjöström.   

Abstract

Mesh：

Substances：

Year:  1994        PMID： 7995331     DOI： 10.1007/BF00196121

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  4 in total

1.  Pharmacokinetics of intravenous 2-mercaptopropionylglycine in man.

Authors:  S M Carlsson; T Denneberg; B M Emanuelsson; B Kågedal; S Lindgren
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Pharmacokinetics and bioavailability of 2-mercaptopropionylglycine administered intravenously and orally in dogs.

Authors:  A Hoppe; T Denneberg; B M Emanuelsson; B Kågedal; S Lindgren
Journal:  J Vet Pharmacol Ther       Date:  1991-12       Impact factor: 1.786

3.  Pharmacokinetics of oral tiopronin.

Authors:  M S Carlsson; T Denneberg; B M Emanuelsson; B Kågedal; S Lindgren
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

4.  The pharmacokinetics of tiopronin and its principal metabolite (2-mercaptopropionic acid) after oral administration to healthy volunteers.

Authors:  B Hercelin; P Leroy; A Nicolas; C Gavriloff; D Chassard; J J Thébault; M T Reveillaud; M F Salles; P Netter
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953
  4 in total
  1 in total

1.  The pharmacokinetics of tiopronin as such is unknown.

Authors:  M S Carlsson; T Denneberg; B M Emanuelsson; B Kågedal; S Lindgren
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.